Latest Genmab Stories
COPENHAGEN, Denmark, Aug.
DUBLIN, July 28, 2014 /PRNewswire/ -- Research and Markets has announced the
LONDON, June 10, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
In a head-to-head comparison of two Food and Drug Administration-approved drugs for the treatment of relapsed chronic lymphocytic leukemia (CLL), ibrutinib significantly outperformed ofatumumab as a second-line therapy.
LONDON, April 17, 2014 /PRNewswire/ -- GlaxoSmithKline plc (LSE: GSK) and Genmab A/S (OMX: GEN) announced today that the U.S.
TUCSON, Ariz., April 3, 2014 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the
DUBLIN, March 13, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/43nvqj/cancer_monoclonal) has announced the addition of the "Cancer
DUBLIN, January 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/ztm9m5/antibodydrug) has announced the addition of the "Antibody-Drug
- The horn of a unicorn considered as a medical or pharmacological ingredient.
- A winged horse with a single horn on its head; a winged unicorn.